• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lilly pitches plan to overcome key patent losses

Lilly pitches plan to overcome key patent losses

July 8, 2011
CenterWatch Staff

Eli Lilly, only months away from losing patent protection for its top-selling drug, told investors the keys to overcoming this and other patent losses lie in its labs and emerging markets including China, according to Mercury News.

The company has 33 potential drugs in mid- or late-stage testing in its development pipeline. Company leaders said during a webcast of a Wall Street analysts meeting that while revenue may dip in the next few years, they expect some of these drugs to fuel growth after 2014.

They also expect strong growth from Japan, the company's animal health business and countries such as China, which has a growing middle class that will fuel a demand for new treatments.

The strategy Lilly outlined was nothing new to analysts, many of whom question the company's reliance on its labs to replace lost sales. They have said pipeline failures could pressure the company into a big acquisition or a reduction in its quarterly dividend, which stands at 49 cents per share.

Lilly reiterated it has no plans for a large-scale deal or to diversify outside its core business. It also said it expects to maintain its dividend "at least at its current level."

Patent expirations will sweep over the pharmaceutical industry in the next few years. Competitors including the world's largest drug maker, Pfizer, and Merck have made major acquisitions or trimmed R&D expenses to deal with the impending revenue loss.

Lilly is an "outlier" among major pharmaceutical companies because it hasn't chosen similar paths, said Erik Gordon, an analyst and professor at University of Michigan's Ross School of Business,

Gordon said in an email that Lilly Chairman and CEO John C. Lechleiter is the "bravest CEO in major pharma" for sticking with this approach.

Bernstein analyst Dr. Tim Anderson said in a note Lilly's pipeline remains incapable of replacing patent-related losses. He projects annual sales of the antipsychotic Zyprexa, Lilly's top seller, to fall from $5 billion last year to about $1.4 billion by 2020.

Lilly loses U.S. patent protection for Zyprexa in October. In the next two years, the drug maker will lose U.S. patents protecting drugs that produced 46% of its 2010 revenue.

It expects patent expirations to reduce annual revenue by about $7 billion from 2010 to 2014. But the company plans to counter that with growth in emerging markets including Russia, Brazil and Mexico. The company said it is building a diabetes research center in China, where it expects to reach $1 billion in sales by 2015.

Lechleiter also told analysts about 10,000 baby boomers turn 65 every day in the U.S., and they will need medicines to keep them active and productive.

Lilly has nine potential drugs in late-stage testing, including cancer treatments ramucirumab and enzastaurin.

But analysts have noted that drugs in late-stage testing offer no guarantee of regulatory approval, and Lilly has had some notable failures at that stage, including a potential Alzheimer's treatment it stopped developing last year.

The drugmaker also said Thursday it remains on track to cut costs by $1 billion by the end of this year. It employed 38,165 people at the end of the first quarter, a roughly 10% drop from the more than 42,000 employees it had five years ago.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing